or Try an Advanced Search...

    Nervous System Disorders Stocks List

    Symbol Grade Name % Change
    SAGE F Sage Therapeutics, Inc. 6.60
    IRWD F Ironwood Pharmaceuticals, Inc. 2.99
    PASG F Passage Bio, Inc. -5.78
    DRRX F DURECT Corporation 17.09
    TRVN F Trevena, Inc. 7.14
    SAVA D Cassava Sciences, Inc. -17.71
    ACAD D ACADIA Pharmaceuticals Inc. 1.17
    BEAM D Beam Therapeutics Inc. 6.23
    PRTC C PureTech Health plc 3.54
    VNDA C Vanda Pharmaceuticals Inc. 3.04
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Central Nervous System Disorders Biopharmaceutical Schizophrenia Alzheimer's Disease Chemical Compounds Chronic Pain Organic Compounds Pain Biology Biomarkers Biotechnology Cardiovascular Disease Chronic Disease Clinical Development Gastrointestinal Medication Opioids Parkinson's Disease Psychiatry Psychosis

    Related ETFs - A few ETFs which own one or more of the above listed Nervous System Disorders stocks.

    Symbol Grade Name Weight
    PSIL C AdvisorShares Psychedelics ETF 4.78
    ARKG F ARK Genomic Revolution Multi-Sector ETF 4.01
    FBT C First Trust Amex Biotech Index Fund 3.85
    GNOM F Global X Genomics & Biotechnology ETF 3.6
    PTH C Invesco DWA Healthcare Momentum ETF 3.28
    View all Nervous System Disorders ETFs...
    Compare ETFs
    Compare ARKG to FBT Compare ARKG to GNOM Compare FBT to GNOM

        Nervous System Disorders Stocks Recent News

        Date Stock Title
        Nov 22 SAGE Sage Therapeutics price target lowered to $4 from $7 at BofA
        Nov 21 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
        Nov 21 SAGE Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
        Nov 21 SAGE Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
        Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
        Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
        Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
        Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
        Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
        Nov 20 PRTC PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
        Nov 20 SAGE Sage’s string of research failures continues
        Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
        Nov 19 SAGE CNS Drug Development: Same As It Ever Was
        Nov 18 SAVA Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears
        Nov 18 SAVA Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Central Nervous System Disorders Biopharmaceutical Schizophrenia Alzheimer's Disease Chemical Compounds Chronic Pain Organic Compounds Pain Biology Biomarkers Biotechnology Cardiovascular Disease Chronic Disease Clinical Development Gastrointestinal Medication Opioids Parkinson's Disease Psychiatry Psychosis
        Nervous System Disorders

        Nervous system disorders are conditions that affect the functioning of the brain, spinal cord, and nerves. These disorders can affect the way the body moves, senses, thinks, and behaves. Examples of nervous system disorders include Alzheimer's disease, epilepsy, Parkinson's disease, multiple sclerosis, stroke, and spinal cord injuries.

        Browse All Tags